Injectable Anti-diabetic Drugs Market Size
| Study Period | 2018-2029 |
| Market Size (2024) | USD 38.79 Billion |
| Market Size (2029) | USD 45.10 Billion |
| CAGR (2024 - 2029) | > 3.00 % |
| Fastest Growing Market | North America |
| Largest Market | North America |
| Market Concentration | Low |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Injectable Anti-diabetic Drugs Market Analysis
The Injectable Anti-diabetic Drugs Market size is estimated at USD 38.79 billion in 2024, and is expected to reach USD 45.10 billion by 2029, growing at a CAGR of greater than 3% during the forecast period (2024-2029).
The COVID-19 pandemic co-morbidities included hypertension, diabetes, cardiovascular disease, and cancer. According to an article,” 89-LB: COVID-19 Outcomes in Patients Who Started GLP1-RAs during Hospitalization,” published by the American Diabetes Association in June 2022, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) were considered beneficial in improving COVID-19 outcomes due to their anti-inflammatory properties. Patients admitted for severe interstitial bilateral pneumonia in the COVID-19 ward due to SARS-COV2 infection and having type 2 diabetes or in-hospital hyperglycemia were treated with GLP-1 RAs in addition to standard therapy.
Diabetes is a chronic condition characterized by high levels of glucose in the blood caused by the inability to produce insulin or use insulin effectively, or both. The main types of diabetes are type 1 diabetes and type 2 diabetes. For a patient with type 1 diabetes, insulin therapy is important for replacing the insulin that the body doesn't produce. People with type 2 diabetes or gestational diabetes need insulin therapy if other treatments, such as diabetes medications and other lifestyle changes, are not able to keep blood glucose levels within the desired range. Diabetes treatment aims to maintain healthy blood glucose levels to prevent both short and long-term complications, such as cardiovascular disease, kidney disease, blindness, and lower limb amputation.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a class of medications used for the treatment of type 2 diabetes, and some drugs are also approved for obesity. One of the benefits of this class of drugs over older insulin secretagogues, such as sulfonylureas or meglitinides, is that they have a lower risk of causing hypoglycemia. Besides being important glucose-lowering agents, GLP-1RAs have significant anti-inflammatory and pulmonary protective effects and an advantageous impact on gut microbes’ composition.
In November 2022, the EU Commission and its members demonstrated political commitment. They set ambitious targets to “reduce inequalities between EU citizens and improve the care and quality of life of people living with diabetes.” The experts emphasized the importance of ensuring effective, accessible, and uninterrupted treatments to reduce the risk of developing complications. The authors of the resolution also emphasized the importance of data collection standardization. They highlighted the role of the Commission’s ‘Healthier Together’ initiative, launched in December 2021, which aimed to prevent, manage, and treat non-communicable diseases. The resolution calls on member states to develop, implement, and monitor national diabetes plans and strategies with” comparable milestones and targets” in recognition of inequalities in public health strategies and care as well as access to healthy and sustainable food across member states.
Therefore, owing to the factors above, the studied market is anticipated to witness growth over the analysis period.
Injectable Anti-diabetic Drugs Market Trends
Dulaglutide Segment Occupied the Highest Market Share in the Injectable Anti-diabetic Drugs Market in the current year
The Dulaglutide segment held the highest share in the injectable anti-diabetic drugs market in the current year.
According to the International Diabetes Federation's (IDF) latest estimates, the adult diabetes population is approximately 537 million, and this number is going to increase by 643 million in 2030. Technological advancements have increased over the period, leading to several modifications either in the GLP-1RA drug or the formulations being developed.
GLP1RAs have been available internationally and are recommended for use when escalation of treatment for type 2 diabetes is required after metformin and lifestyle management. They can be safely used with all other glucose-lowering therapies except vildagliptin. Dulaglutide (Trulicity) is a weekly subcutaneous GLP1RA that is highly effective for reducing HbA1c with additional weight loss and cardiorenal protection benefits. Therapy with dulaglutide allows many patients to reach and maintain target HbA1c without insulin and/or sulfonylureas, eliminating the associated hypoglycemia risk. GLP1RAs elicit greater weight reduction and are recommended over SLGT2 inhibitors when cerebrovascular disease other than heart failure or renal disease predominates.
Dulaglutide is fully funded for patients meeting special authority criteria in some countries. For instance, New Zealand guidelines recommend offering GLP1RAs to all patients with HbA1c levels above target, especially when GLP1RA use would provide additional reductions in cardiovascular risk and/or permit reduction or cessation of other therapies that contribute to weight gain or hypoglycemia.
Owing to the rising rate of obesity, growing genetic factors for type-2 diabetes, and the increasing prevalence and government support initiatives, it is likely that the market will continue to grow.
North American region held the highest market share in the Injectable Anti-diabetic Drugs Market in the current year
North America held the highest market share in the Injectable Anti-diabetic Drugs Market in the current year.
The Centers for Disease Control and Prevention (CDC) National Diabetes Statistics Report 2022 estimated that more than 130 million adults are living with diabetes or prediabetes in the United States. Type 2 diabetes is more common, and diabetes is more consequential among communities of color, those who live in rural areas, and those with less education, lower incomes, and lower health literacy.
Health Canada is the third regulatory agency to provide more options for people interested in GLP-1 agonists. It approved the first and only GLP-1 agonist pill (Rybelsus by Novo Nordisk) for people with type 2 diabetes recently after approval by the European Medicines Agency and approval in the U.S. GLP-1 RAs can be taken alone or in combination with other treatments for type 2 diabetes to improve blood glucose management, i.e., time in range, in addition to lowering blood glucose, they benefit heart health by reducing the risk of heart attack, stroke, and heart-related death. This is important because people with type 2 diabetes are at substantially higher risk of heart disease than those without diabetes.
Furthermore, the market players are adopting various strategies such as collaborations, partnerships, mergers, acquisitions, and expansions for new products to increase market share. For instance, Eli Lilly and Boehringer Ingelheim together have an alliance in developing and commercializing Basaglar (Insulin Glargine). However, the companies are working on various innovations such as Biocon is developing Insulin Tregopil, an oral prandial insulin tablet, for the treatment of type-1 and type-2 diabetes mellitus. The fast-acting oral insulin could improve post-prandial glucose control with reduced side effects and greater adherence, thus holding the promise to transform type-1 management. Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, is working to bring the first oral insulin.
The variables mentioned above, together with the increased incidence of diabetes caused by inactivity, are anticipated to propel the market forward during the projected time.
Injectable Anti-diabetic Drugs Industry Overview
The injectable anti-diabetic drugs market is consolidated, with major manufacturers, namely Eli Lilly, Novo Nordisk, and Sanofi, among others, holding a presence in all regions. Mergers and acquisitions that have happened between the players in the recent past helped the companies strengthen their market presence. For instance, Eli Lilly and Boehringer Ingelheim together have an alliance in developing and commercializing Basaglar (insulin glargine).
Injectable Anti-diabetic Drugs Market Leaders
-
Novo Nordisk
-
Lilly
-
Julphar
-
Biocon
-
Sanofi
*Disclaimer: Major Players sorted in no particular order
Injectable Anti-diabetic Drugs Market News
- March 2023: Novo Nordisk announced that the company will drop prices for vials and pens of NovoLog and other insulin brands by 75 percent beginning January 1, 2024, in the United States. The price for some other Novo Nordisk insulin brands will be lowered by 65 percent.
- March 2023: NHS approved Wegovy, a weight loss injection also known as semaglutide. Wegovy mimics the hormone glucagon-like peptide-1 (GLP-1) and suppresses appetite. The NHS is set to offer Wegovy, a weight loss injection also known as semaglutide, to thousands of people living with obesity in England.
Injectable Anti-diabetic Drugs Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Drivers
4.3 Restraints
4.4 Porter's Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 Insulin
5.1.1 Basal or Long-acting Insulins
5.1.2 Bolus or Fast-acting Insulins
5.1.3 Traditional Human Insulins
5.1.4 Combination Insulins
5.1.5 Biosimilar Insulins
5.2 Glucagon-like peptide-1 (GLP-1) agonists drugs
5.2.1 Dulaglutide
5.2.2 Exenatide
5.2.3 Liraglutide
5.2.4 Lixisenatide
5.2.5 Semaglutide
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Rest of North America
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 Spain
5.3.2.3 Italy
5.3.2.4 France
5.3.2.5 United Kingdom
5.3.2.6 Russia
5.3.2.7 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 Japan
5.3.3.2 China
5.3.3.3 Australia
5.3.3.4 India
5.3.3.5 South Korea
5.3.3.6 Malaysia
5.3.3.7 Indonesia
5.3.3.8 Thailand
5.3.3.9 Philippines
5.3.3.10 Vietnam
5.3.3.11 Rest of Asia-Pacific
5.3.4 Latin America
5.3.4.1 Brazil
5.3.4.2 Mexico
5.3.4.3 Rest of Latin America
5.3.5 Middle East and Africa
5.3.5.1 South Africa
5.3.5.2 Saudi Arabia
5.3.5.3 Oman
5.3.5.4 Egypt
5.3.5.5 Iran
5.3.5.6 Rest of Middle East and Africa
6. MARKET INDICATORS
6.1 Type-1 Diabetes population
6.2 Type-2 Diabetes population
7. COMPETITIVE LANDSCAPE
7.1 COMPANY PROFILES
7.1.1 Novo Nordisk
7.1.2 Lilly
7.1.3 Biocon
7.1.4 Julphar
7.1.5 Pfizer
7.1.6 Sanofi
- *List Not Exhaustive
7.2 COMPANY SHARE ANALYSIS
8. MARKET OPPORTUNITIES AND FUTURE TRENDS
Injectable Anti-diabetic Drugs Industry Segmentation
Injectable anti-diabetic Drugs composed of GLP-1 receptor agonists are a type of non-insulin medication that is used in combination with diet and exercise to help treat type 2 diabetes and insulin. The injectable anti-diabetic drugs market is segmented into drugs (dulaglutide, exenatide, ligarglutide, lixisenatide, and semaglutide), brands (byetta, bydureon, victoza, trulicity, lyxumia, and ozempic), and geography (North America, Europe, Asia-Pacific, the Middle East and Africa, and Latin America). The report offers the value (in USD) and volume (in units) for the above segments.
| Insulin | |
| Basal or Long-acting Insulins | |
| Bolus or Fast-acting Insulins | |
| Traditional Human Insulins | |
| Combination Insulins | |
| Biosimilar Insulins |
| Glucagon-like peptide-1 (GLP-1) agonists drugs | |
| Dulaglutide | |
| Exenatide | |
| Liraglutide | |
| Lixisenatide | |
| Semaglutide |
| Geography | |||||||||||||
| |||||||||||||
| |||||||||||||
| |||||||||||||
| |||||||||||||
|
Injectable Anti-diabetic Drugs Market Research FAQs
How big is the Injectable Anti-diabetic Drugs Market?
The Injectable Anti-diabetic Drugs Market size is expected to reach USD 38.79 billion in 2024 and grow at a CAGR of greater than 3% to reach USD 45.10 billion by 2029.
What is the current Injectable Anti-diabetic Drugs Market size?
In 2024, the Injectable Anti-diabetic Drugs Market size is expected to reach USD 38.79 billion.
Who are the key players in Injectable Anti-diabetic Drugs Market?
Novo Nordisk, Lilly, Julphar, Biocon and Sanofi are the major companies operating in the Injectable Anti-diabetic Drugs Market.
Which is the fastest growing region in Injectable Anti-diabetic Drugs Market?
North America is estimated to grow at the highest CAGR over the forecast period (2023-2029).
Which region has the biggest share in Injectable Anti-diabetic Drugs Market?
In 2023, the North America accounts for the largest market share in Injectable Anti-diabetic Drugs Market.
What years does this Injectable Anti-diabetic Drugs Market cover, and what was the market size in 2023?
In 2023, the Injectable Anti-diabetic Drugs Market size was estimated at USD 37.63 billion. The report covers the Injectable Anti-diabetic Drugs Market historical market size for years: 2018, 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Injectable Anti-diabetic Drugs Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Injectable Anti-diabetic Drugs Industry Report
Statistics for the 2024 Injectable Anti-diabetic Drugs market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Injectable Anti-diabetic Drugs analysis includes a market forecast outlook to for 2024 to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
